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Table
Features at Diagnosis
Stratum A Stratum B
n ¼ 37 n ¼ 13
Age, days 34 (0 - 304) 74 (0 - 4916)
Gender (M / F) 28 / 9 4 / 9
Trigger of Dx
FH 27% 15%
NBS 32% 8%
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S161hematopoietic stem cell transplantation (HSCT). Transplant-
associated risks are one of many barriers to the widespread
use of HSCT for SCA. Over 20 years ago, Kodish et al reported
on parent attitudes towards HSCT for their childrenwith SCA.
Since the risks of matched sibling donor HSCT for SCA are
now better deﬁned and community awareness of HSCT as
a therapeutic option has increased, parent and patient
perceptions of HSCT may have changed.
Methods: To assess current attitudes toward HSCT, we con-
ducted a survey of parents of childrenwith SCA (Hgb SS or S-B0
thal) and teenagers with SCA by using questions based on the
standard reference gamble paradigmandbycomparing survey
responses between African (A) and African American parents
(AA) and between parents and their adolescent children. SCA
severity was assessed based on their self-reported history of
sickle cell disease related complications and hospitalizations.
Results: 89 parents and adolescents (54 parents, 3 patients
and 16 parent-adolescent dyads) were surveyed after
a discussion of the process and outcomes of HSCT and its
attendant risks. 72% of respondents were willing to accept >
5% risk of mortality. 57% of respondents were willing to
accept a risk of 10% or more GVHD. 20/89 (22%) respondents
were unwilling to accept any risk of mortality or GVHD. Risk
averseness did not differ amongst respondents of A or AA
origin. There was no correlation between self reported SCA
severity and acceptance of higher mortality or GVHD risk.
56% of respondents were willing to accept infertility post
BMT regardless of SCA severity or country of origin. Of those
whowerewilling to accept at least a 5% risk of mortality, 75%
were willing to accept a GVHD risk of at least 10%.
Conclusions: These data suggest that the majority of parents
and adolescents are willing to accept the current morbidity
and mortality risks associated with matched sibling HSCT to
achieve a cure of SCA regardless of disease severity. Although
attitudes towards HSCT for SCA have changed over the last 2
decades, there are still signiﬁcant numbers of parents and
adolescents who are unwilling to accept any risk of mortality
or GVHD in order to cure their SCA.Infection 38% 54%
Other 3% 23%
Maternal Engraftment 53% 0%
Autoimmunity 3% 42%
FTT 24% 33%
ALC 1175 (3 - 10120) 1078 (700- 3700)
CD3 6 (0-8898) 1918 (45 - 6589)
CD4 4 (0 - 1307) 474 (31 - 2138)
CD4/CD45RA 0 (0 - 57) 43 (0 - 474)
CD4/CD45RO 1 (0 - 155) 1035 (196 - 1975)
CD8 4 (0 - 750) 78 (0 - 900)
PHA (% lower limit nl) 0 (0 - 20) 12 (0 - 126)
TRECs (#/uL) 0 (0 - 11) 0
B Cells: B+ Phenotype 1171 (164 - 3847);
n ¼ 29
2 (0 - 822)
B- Phenotype 7 (0 - 186); n ¼ 8
IgG (mg/dL), pre-IVIG 539 (0 - 928) 608 (371 - 1030)
IgM (mg/dL) 10 (0 - 89) 13 (0 - 95)
IgA (mg/dL) 7 (0 - 25) 7 (0 - 165)
IgE (IU/mL) 2 (0 - 79) 445 (0 - 20400)
NK Cells: NK+ Phenotype 266 (28 - 939);
n ¼ 12
282 (32 - 734)
NK- Phenotype 16 (0 - 407);
n ¼ 25
IL-2RG 19 0
JAK3 2 1
RAG-1/2 5 7
Artemis 0 1
IL-7R 3 0
CD3d 3 0
ADA 3 0
AK2 0 1
Unknown 1 3
Numbers ¼ median (range); Cells ¼ (x 106/L)93
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ThePIDTCconsists of 32 centers inNorthAmerica that care
for patients with PID. The 6901 study's hypothesis is that the
analysis of uniform data on patients with SCID will identifythose variables that contribute to thebest outcomes following
treatment.Wereportbaseline clinical, immunologic&genetic
features of the 1st 50 patients enrolled & the initial therapies
that they received, to summarize for the ﬁrst time the current
practice in the diagnosis & treatment of SCID.
From 8/2010 - 5/2012 patients with suspected SCID
underwent work-up and therapy per local center practices.
After consent, diagnostic information was reviewed by the
eligibility and stratiﬁcation panel. Stratum A is classic SCID.
Stratum B is leaky SCID, Omenn Syndrome or Reticular
Dysgenesis. HCT details were obtained from the CIBMTR.
Presenting features of the1st 50patients are shown(Table).
92% hadmutations in a known SCID gene. Those diagnosed by
newborn screen (NBS) or family history (FH) were younger
than those diagnosedby clinical signs (median 15 vs.181days;
P0.0001)andwent toHCTat amedianof67daysvs. 214days
(P  0.0001), though there was no difference in time from
diagnosis to HCT (median 56 vs. 43 days; P ¼ 0.28). 92% were
treated with HCT at a median of 25 days from diagnosis for
matched related (n ¼ 7) or 29 days mismatched related
(n¼ 12) donors, vs. 61 days for unrelated adult (n ¼ 13) or 60
days for cord blood (n ¼ 14) donors (P ¼ 0.02). Conditioning
was none (n ¼ 10), serotherapy alone (n ¼ 4); reduced inten-
sity (n¼ 9), or myeloablative (n¼ 23). 3 patients were treated
with gene therapy & 1 with enzyme-replacement.
Future directions include continued enrollment with
a goal of >250 patients & analysis of short and long-term
outcomes of therapy to identify which factors are beneﬁcial
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166S162or deleterious to survival, T- and B-cell reconstitution &
clinical outcome after treatment for SCID & what biomarkers
are predictive of these outcomes.
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Introduction: The biology of engraftment syndrome (ES) is
poorly understood and the degree of overlap with GVHD is
unclear.
Methods: To better understand ES, plasma cytokine proﬁles
were evaluated in 52 consecutive pediatric allogeneic bone
marrow transplant recipients prior to transplant, on the day
of stem cell infusion and weekly until day+100. Patients were
divided into three groups, those with isolated engraftment
syndrome (n¼4), acute graft versus host disease without
prior ES (n¼12) and with neither engraftment syndrome nor
acute graft versus host disease (n¼32). Cytokine values were
expressed as mean fold increase from pre transplant values.
Results: Median age of recipients was 6.7 years (range 0.6-
19.4). ES was observed a median of 12.5 days (range 11-15)
after transplant, while aGVHD was diagnosed at median of
55 days (range 19-95 days) after transplant. MCP-1 and
MIP1b were signiﬁcantly elevated in patients with ES during
the ﬁrst two weeks, while remaining unchanged or reduced
in either of the other 2 cohorts. Moreover, while various
cytokines were found to be elevated in patients who devel-
oped aGVHD, the degree of elevation was signiﬁcantly
exaggerated in patients with isolated ES during 4 weeks
post-transplant. (See table 1)
Conclusion: MCP-1 and MIP1b are elevated speciﬁcally in ES
suggesting a separate biology from GVHD. In addition, the
degreeofelevationofpro-inﬂammatorycytokines ismarkedly
greater in children with ES compared to those with GVHD.
Figure 1. MIP1bandMCP1 inpatientswithES, aGVHDandneitherGVHDnorES.Table 1
Cytokine proﬁles in ES, aGVHD and patients with neither ES nor GVHD at 4
weeks after transplant
Cytokine Neither ES nor
GVHD (Mean
fold increase
from pre
transplant
value)
GVHD (Mean
fold increase
from pre
transplant
values)
ES (Mean fold
increase from
pre transplant
values)
P-value
(ES vs
GVHD)
IL1b 0 2 36 <.01
IL4 2 5 40 <.001
IL7 8 6 138 <.01
IL12 14 4.6 108 <.01
IL13 2.8 3 62 <.0195
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Matched related hemopoietic stem cell transplantation
(MRD-HSCT) for patients with Primary Immunodeﬁciencies
(PIDs) has been life saving. There is less information regarding
stem cell transplantation from unrelated donors including
umbilical cord blood units. We report the outcome following
HSCT (1998-2012) in 69 patients with PIDs: SCID (n¼35),WAS
(n¼9), Phagocytic disorders (CGD (n¼17), LAD (n¼4)); and
other (n¼4; one each; Interferon g receptor deﬁciency, Hyper
IgM syndrome, Autosomal recessive Hyper IgE syndrome
(Dock 8 mutation), and reticular dysgenesis). The median age
at transplant was 1 year (range, 0.1-17 years). Twenty patients
received an MRD graft, 22 patients received a matched unre-
lated donor graft (MUD), 4 patients received a mismatched
unrelated donor graft, 15 patients received a haploidentical
related donor graft and 9 patients received a mismatched
unrelated cord blood unit (MMUCB). One patient received
a MMUCB after a haploidentical graft failure. 58 patients
received ablative conditioning regimen with busulfan, cyclo-
phosphamide, and ﬂudarabine or cytarabine. Six patients
received reduced intensity conditioning using ﬂudarabine
with anti-CD52 or/and anti-CD45. Six SCID patients were not
conditioned. 52 patients received anti-CD52; no serotherapy
was given forMMUCB grafts. Graft versus host disease (GvHD)
prophylaxis combined cyclosporine and methotrexate or
cyclosporine and prednisone except for MUCB recipients who
were given cyclosporine and MMF as prophylaxis. Engraft-
ment: Forty ﬁve of 67 evaluable patients (65%) achieved full
donor chimerism (>90%) of all cell lineages including T cells.
Twelve patients had primary graft failure. 10 were hap-
loidentical grafts and 2 were MUD grafts. All except one were
rescued with a repeat stem cell infusion. Just 3/67 patients
developedgrade II-IVaGvHDandnopatientdevelopedchronic
GvHD. Survival.With amedian followupof 4 years (range, 0.3-
12 years), overall survival was: 95% and 86%, for phagocytic
disordersandSCIDs respectively; and77%and75% forWASand
other diseases, respectively. Recipients of MRD and UCB had
100% survival:MUDgraft recipients had an 88% survival, while
recipients of mismatched unrelated or haploidentical related
transplants, had 50% and 71% survival respectively. Infection
was the commonest cause of death. Hence excellent overall
survival for PID patientsmay be obtained after unrelated HSCT
and results usingmatched related grafts andmismatched cord
blood units are highly comparable.96
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